June 5, 2015
A US appeals court has blocked Novartis from selling the first biosimilar to be approved in the United States.
June 4, 2015
Will Sandoz' biosimilar, first ever in the US, ever see the light of day?
May 14, 2015
While the marketing of the first biosimilar to be approved in the US market, Zarxio, has been delayed due to a court order, the FDA is providing guidance to manufacturers to help them effectively navigate the process of product development.
April 11, 2015
Sandoz's biosimilar will be sold under the trade name Zarxio but the FDA has held off on releasing a naming policy for biosimilars, giving the product a “placeholder nonproprietary name” of “filgrastim-sndz.”
April 9, 2015
Trends in healthcare are driven by innovation, which is largely being driven by specialty innovation, Douglas M. Long, MBA, vice president of industry relations at IMS Health, said during the headline session “Marketplace Trends” at the Academy of Managed Care Pharmacy’s 27th Annual Meeting & Expo.